Assertio Therapeutics WKN: A2N4B9 ISIN: US04545L1070 Kürzel: ASRT

Kurs zur ASSERTIO THERAPEUTICS Aktie
0,745 EUR
+2,05 %+0,015
20. May, 07:58:22 Uhr, Lang & Schwarz
k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Börse: k.A.
k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Börse: k.A.
k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Börse: k.A.
k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Börse: k.A.
k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Börse: k.A.
k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Börse: k.A.
k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Börse: k.A.
k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Börse: k.A.
Anzeige
Alles ab 0 Euro pro Order. Dauerhaft.
Smartbroker
Chemical
Chemical, 11.05.2020 14:44
Assertio Therapeutics EPS beats by $0.18, beats on revenue https://seekingalpha.com/news/3572647-assertio-therapeutics-eps-beats-0_18-beats-on-revenue
Chemical
Chemical, 15.02.2020 8:29
Assertio Therapeutics: A Biotech Stock Trading Below Its Cash Balance https://seekingalpha.com/article/4324469-assertio-therapeutics-biotech-stock-trading-below-cash-balance Takeaway ASRT has seen its fair share of woes, from the recent rejection of its cosyntropin sNDA, to below-average data readout on collaboration project IW-3718, and to a staggering -20% Y/Y decline on core product revenues. On the other hand, the recent sale of Nucynta for $375M removes all remaining debt from the company's balance sheet, causes its stock to trade at negative enterprise value, and adds sizable capital for future R&D efforts. Keep in mind, ASRT is estimated to continue its profitability after the deal closes, as its remaining products have over 60-80% gross margin. Hence, the author finds the benefit to outweigh the company's drawbacks, and will reiterate the company's buy rating as of today.
Andymac0815
Andymac0815, 06.02.2020 23:08
Letztes Jahr mit Verlust raus 🤤
Chemical
Chemical, 06.02.2020 22:04
Assertio Therapeutics Announces Sale of NUCYNTA® Franchise to Collegium Pharmaceutical for $375.0 Million https://newsfilter.io/a/3d0fa5d5f5e45ad603002142755aedb8
Billi1
Billi1, 13.01.2020 15:43
😎
Chemical
Chemical, 13.01.2020 14:21
👀
Chemical
Chemical, 13.01.2020 14:20
Assertio Therapeutics Sees FY19 Neurology Franchise Sales Above Guidance Range Of $102M-$105M
Kommentare
1 DEPOMED Hauptdiskussion
Kursdetails
Geld (bid) 0,735 (6.854)
Brief (ask/offer) 0,755 (6.854)
Spread 2,649
Geh. Stück 0
Eröffnung 0,730
Vortag 0,730
Tageshoch 0,745
Tagestief 0,730
52W Hoch 3,960
52W Tief 0,508
Tagesvolumen
in EUR gehandelt 2.000 Stk
Gesamt 2.000 Stk
Anzeige
Smartbroker
Der Broker von Deutschlands größter Finanzcommunity
Geld/Brief Kurse
Börse Geld Brief Zeit Volumen Kurs
Tradegate 0,710 0,745 1589919991 19. May 2.000 Stk 0,730 EUR
ges. 2.000 Stk
Realtime / Verzögert
Börsennotierung
Marktkapitalisierung in EUR
59,4 Mio.
Anzahl der Aktien
81,4 Mio.
Grundlegende Daten zur ASSERTIO THERAPEUTICS Aktie
Finanzdaten 2018 2019 2020 2021 2022e 2023e 2024e
KUV - - - - - - -
Ergebnis je Aktie (bereinigt) - - - - - - -
Cashflow - - - - - - -
Eigenkapitalquote - - - - - - -
Verschuldungsgrad - - - - - - -
Eigenkapitalrendite - - - - - - -
Gesamtkapitalrendite - - - - - - -
EBITDA - - - - - - -
EBIT - - - - - - -
Fundamentaldaten 2018 2019 2020 2021 2022e 2023e 2024e
KCV - - - - - - -
Dividendenrendite - - - - - - -
Kurs-Gewinn-Verhältnis (KGV) - - - - - - -
Dividende je Aktie - - - - - - -
Bilanzdaten 2018 2019 2020 2021 2022e 2023e 2024e
Netto-Provisionsüberschuss - - - - - - -
Umsatzerlöse - - - - - - -
Ergebnis vor Steuern - - - - - - -
Steuern - - - - - - -
Ausschüttungssumme - - - - - - -
Nettoverzinsung - - - - - - -
Zinsertrag - - - - - - -
Gesamtertrag - - - - - - -
BörsennewsApp
BörsennewsApp im Google Play Store
BörsennewsApp im Apple Store

© 2022 börsennews.de

Daten und Kurse:

TTMzero RealTime

SIX Financial Information SIX Financial Information

Zeitverzögerung der Kursdaten: Deutsche Börsen +15 Min. NASDAQ +15 Min. NYSE +20 Min. AMEX +20 Min. Dow Jones +15 Min. Alle Angaben ohne Gewähr.